Scienture Holdings, Inc. (SCNX): Nasdaq/NYSE listing notice — TRxADE HEALTH gets Nasdaq non-compliance notice for minimum bid price; also fails equity requirement

Scienture Holdings, Inc.

Received Nasdaq notice Nov 29, 2022 for bid price below $1.00 for 30 consecutive business days through Nov 28, 2022.
Has 180 days until May 29, 2023 to regain compliance by closing at $1.00 for 10 consecutive business days.
Also not in compliance with $2.5M minimum stockholders' equity requirement; must complete transactions by Jan 25, 2023.
To satisfy equity rule, company completed $1.75M stock sale Oct 7, 2022; must evidence compliance by Jan 25 deadline.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 29, 2022, TRxADE HEALTH, Inc. (the “ Company ”, “ we ” or “ us ”) received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price re

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-034200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.